Alvotech Stock Hits Day Low of $3.75 Amid Price Pressure

Alvotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced significant volatility today, with the stock hitting an intraday low of USD 3.75. The stock has declined by 8.73% on June 16, 2026, contrasting sharply with the S&P 500's modest decline of 0.57% for the same day. Over the past week, Alvotech's performance has also been underwhelming, down 6.97%, while the S&P 500 has gained 1.69%. In the longer term, the stock has faced considerable challenges, with a year-to-date decline of 24.56% compared to the S&P 500's 9.73% increase. Notably, Alvotech's one-year performance shows a staggering drop of 58.57%, starkly underperforming the S&P 500's 24.5% gain. Financial metrics reveal a negative book value and a weak long-term growth outlook, with net sales growing at an annual rate of 256.02% over the last five years. However, the company's ability to service its debt remains a concern, highlighted by a poor EBIT to interest ratio of -7.56. As Alvotech navigates these challenges, its market position continues to reflect significant pressures.